Introduction de Mainstay Medical sur Euronext

Paris – 29 April 2014 – Euronext, a wholly owned subsidiary of IntercontinentalExchange Group (NYSE: ICE), today announced the listing of Mainstay Medical International plc. Mainstay Medical is listed on Euronext’s regulated market in Paris (Compartment C) and on the Entreprise Securities Market of the Irish Stock Exchange in Dublin (ticker symbol: MSTY, ISIN: IE00BJYS1G50).

Mainstay Medical is an Irish producer of medical devices with operations in Ireland, Australia and the United States. It was founded in 2008 to develop innovative neurostimulation therapies for the treatment of chronic and debilitating lower back pain, and has focused on developing ReActic8®, an implantable neurostimulation device (AIMD) for patients suffering from debilitating low back pain.

Mainstay Medical was listed through the admission to trading of the 3,404,702 ordinary shares making up the company’s equity and the 851,175 new shares issued under the Offering[1].

The admission and issue price of Mainstay Medical shares was set at €21.15 per share. Market capitalisation was around €90 million based on the Offering price. Altogether the offering raised €18 million.

“We are delighted to welcome Mainstay Medical to Euronext and to accompany the company as it enters a new phase in developing its innovative therapy for patients suffering from chronic low back pain. Listing will raise the company’s profile with investors, while generating the capital it needs to deploy its growth projects,” said Albert Ganyushin head of international listings at Euronext.

Dr. Oern Stuge, Chairman of the Board of Directors at Mainstay Medical, said: “Our successful listing is a milestone, and as a listed company we are now poised to move up to the next stage. We are delighted with the very positive response from institutional and individual investors who recognised that Mainstay Medical’s unique and innovative approach to treating chronic low back pain, in addition to meeting a major clinical need, also offers an attractive investment opportunity. We have recently launched clinical trials for ReActiv8® and are dedicated to pursuing our strategy aimed at winning the necessary regulatory approvals for marketing our products.”

Press Release Footer

About Euronext
Euronext is the leading pan-European market infrastructure, connecting European economies to global capital markets, to accelerate innovation and sustainable growth. It operates regulated exchanges in Belgium, France, Ireland, Italy, the Netherlands, Norway and Portugal. With nearly 1,900 listed issuers and around €6.3 trillion in market capitalisation as of end September 2024, it has an unmatched blue-chip franchise and a strong diverse domestic and international client base. Euronext operates regulated and transparent equity and derivatives markets, one of Europe’s leading electronic fixed income trading markets and is the largest centre for debt and funds listings in the world. Its total product offering includes Equities, FX, Exchange Traded Funds, Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. The Group provides a multi-asset clearing house through Euronext Clearing, and custody and settlement services through Euronext Securities central securities depositories in Denmark, Italy, Norway and Portugal. Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. In addition to its main regulated market, it also operates a number of junior markets, simplifying access to listing for SMEs.
For the latest news, follow us on Twitter (twitter.com/euronext) and LinkedIn (linkedin.com/euronext).

_Disclaimer
_{This press release is for information purposes only and is not a recommendation to engage in investment activities. This press release is provided “as is” without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext’s subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext.}

_{This press release speaks only as of this date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is located at}_{www.euronext.com/terms-use}_.